Long-Term Debt and Other Financings - Novartis Note - Additional Information (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Jan. 31, 2014 |
May. 31, 2005 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
|
| Novartis Note [Member] | |||||
| Debt Instrument [Line Items] | |||||
| Maturity date | Jun. 30, 2015 | ||||
| Research and development expenses funded through loan facility, maximum | 75.00% | ||||
| Maximum borrowing capacity under loan agreement | $ 50,000,000 | ||||
| Interest rate at period end | 2.81% | ||||
| Accrued interest payable | $ 300,000 | $ 300,000 | $ 400,000 | ||
| Percentage of milestone received | 25.00% | ||||
| Milestone received under the collaboration agreement | $ 7,000,000 | ||||
| Repayment of debt | $ 1,750,000 | ||||
| Outstanding principal balance | $ 13,700,000 | $ 13,400,000 | |||
| Novartis Note [Member] | Six-month LIBOR [Member] | |||||
| Debt Instrument [Line Items] | |||||
| Basis spread on variable rate | 2.00% | ||||
| Secured Note Amendment [Member] | |||||
| Debt Instrument [Line Items] | |||||
| Maturity date | Sep. 30, 2020 | ||||
| Reduction in outstanding principal amount | $ 7,300,000 | ||||
| X | ||||||||||
- Definition Percentage points added to the reference rate to compute the variable rate on the debt instrument. No definition available.
|
| X | ||||||||||
- Definition Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Decrease for amounts of indebtedness forgiven by the holder of the debt instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Increase for accrued, but unpaid interest on the debt instrument for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. No definition available.
|
| X | ||||||||||
- Definition The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company. No definition available.
|
| X | ||||||||||
- Definition The maximum borrowing capacity for a debt instrument under the loan agreement. No definition available.
|
| X | ||||||||||
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. No definition available.
|
| X | ||||||||||
- Definition Refers to percentage of milestone received. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|